,Name,Term,ES,NES,NOM p-val,FDR q-val,FWER p-val,Tag %,Gene %,Lead_genes,Lead_proteins
0,gsea,Metabolism,0.6759243624994932,2.118367441902951,0.0,0.0,0.0,7/18,28.07%,TTR;RBP4;PRELP;GATM;DDAH1;APOA1;LUM,A0A087WT59;A0A087WV45;A6XGL1;A6XMH1;E9KL36;P02766;Q53WY6;Q8TDB2;A0A0C4DGV7;P02753;Q5VY30;P51888;Q6FHG6;Q7Z4B2;A0A024R5Q4;H0YKW9;H0YLC6;H0YMX4;H0YN43;P50440;P50440-2;P50440-3;B1AKK2;B4DYP1;B4E3V1;O94760;O94760-2;A0A024R3E3;F8W696;P02647;Q8TDB0;Q9Y355;P51884;Q53FV4
1,gsea,Disease,0.6813387939417906,1.6620842782209473,0.0,0.04030571338934012,0.054,3/10,7.02%,TTR;RBP4;PRELP,A0A087WT59;A0A087WV45;A6XGL1;A6XMH1;E9KL36;P02766;Q53WY6;Q8TDB2;A0A0C4DGV7;P02753;Q5VY30;P51888;Q6FHG6;Q7Z4B2
2,gsea,Metabolism of proteins,0.751335095629665,1.59634818589654,0.015817223198594025,0.07008110526254634,0.117,7/11,26.32%,TTR;TSPAN14;SERPIND1;ITIH2;AHSG;APOA1;KNG1,A0A087WT59;A0A087WV45;A6XGL1;A6XMH1;E9KL36;P02766;Q53WY6;Q8TDB2;A6NEP9;H7BXY6;Q8N2P5;Q8NG11;Q8NG11-2;Q8NG11-3;P05546;Q8IVC0;A0A087WTE1;A2RTY6;B4DM79;D3DRR6;P19823;Q5T985;Q5T987;B7Z8Q2;C9JV77;P02765;A0A024R3E3;F8W696;P02647;Q8TDB0;Q9Y355;B4DPP8;D3DNU8;P01042-2;P01042-3;Q05CF8
3,gsea,Metabolism of vitamins and cofactors,0.8304709109759859,1.5188134139793257,0.011023622047244094,0.13589561473838324,0.261,2/4,5.26%,TTR;RBP4,A0A087WT59;A0A087WV45;A6XGL1;A6XMH1;E9KL36;P02766;Q53WY6;Q8TDB2;A0A0C4DGV7;P02753;Q5VY30
4,gsea,Transport of small molecules,0.4835237697825389,1.402147573989645,0.05434782608695652,0.37473420016035136,0.597,4/6,47.37%,APOA1;A2M;CP;ATP2A2,A0A024R3E3;F8W696;P02647;Q8TDB0;Q9Y355;B2R950;B7Z7M2;F8W7L3;H0YFH1;P01023;P20742;P20742-2;Q9BQ22;A5PL27;A8K5A4;B3KTA8;B7Z5Q2;D6RE86;H7C5N5;P00450;Q1L857;Q6NSB2;P16615-2
5,gsea,Immune System,0.6204954098610945,1.3918894796235732,0.06957928802588997,0.2874310912359506,0.623,5/9,29.82%,TTR;TSPAN14;CLU;AHSG;A1BG,A0A087WT59;A0A087WV45;A6XGL1;A6XMH1;E9KL36;P02766;Q53WY6;Q8TDB2;A6NEP9;H7BXY6;Q8N2P5;Q8NG11;Q8NG11-2;Q8NG11-3;B4DW11;E5RG36;E5RGB0;E5RH61;E5RJZ5;E7ERK6;E7ETB4;H0YAS8;H0YC35;H0YLK8;P10909;P10909-2;P10909-3;P10909-4;P10909-5;Q6LDQ3;Q8IWL5;Q8IWM0;B7Z8Q2;C9JV77;P02765;B3KP79;B3KWB5;M0R009;P04217;P04217-2;Q7Z3U3;V9HWD8
6,gsea,Innate Immune System,0.6204954098610945,1.3918894796235732,0.06957928802588997,0.2874310912359506,0.623,5/9,29.82%,TTR;TSPAN14;CLU;AHSG;A1BG,A0A087WT59;A0A087WV45;A6XGL1;A6XMH1;E9KL36;P02766;Q53WY6;Q8TDB2;A6NEP9;H7BXY6;Q8N2P5;Q8NG11;Q8NG11-2;Q8NG11-3;B4DW11;E5RG36;E5RGB0;E5RH61;E5RJZ5;E7ERK6;E7ETB4;H0YAS8;H0YC35;H0YLK8;P10909;P10909-2;P10909-3;P10909-4;P10909-5;Q6LDQ3;Q8IWL5;Q8IWM0;B7Z8Q2;C9JV77;P02765;B3KP79;B3KWB5;M0R009;P04217;P04217-2;Q7Z3U3;V9HWD8
7,gsea,Metabolism of carbohydrates,0.6967110984247824,1.3058741966668301,0.16695352839931152,0.8626239673022623,0.868,2/3,28.07%,PRELP;LUM,P51888;Q6FHG6;Q7Z4B2;P51884;Q53FV4
8,gsea,Amyloid fiber formation,0.8044415768262154,1.2972535924954405,0.14982578397212543,0.8466620575328353,0.881,2/3,8.77%,TTR;TSPAN14,A0A087WT59;A0A087WV45;A6XGL1;A6XMH1;E9KL36;P02766;Q53WY6;Q8TDB2;A6NEP9;H7BXY6;Q8N2P5;Q8NG11;Q8NG11-2;Q8NG11-3
9,gsea,Cellular responses to stimuli,0.5892305999785369,1.2959222986898553,0.11586206896551725,0.7061917498264972,0.889,1/3,24.56%,APOA1,A0A024R3E3;F8W696;P02647;Q8TDB0;Q9Y355
10,gsea,Cellular responses to stress,0.5892305999785369,1.2959222986898553,0.11586206896551725,0.7061917498264972,0.889,1/3,24.56%,APOA1,A0A024R3E3;F8W696;P02647;Q8TDB0;Q9Y355
11,gsea,The canonical retinoid cycle in rods (twilight vision),0.9818181818181819,1.2787928016728831,0.09647495361781076,0.627098802012526,0.912,2/2,5.26%,TTR;RBP4,A0A087WT59;A0A087WV45;A6XGL1;A6XMH1;E9KL36;P02766;Q53WY6;Q8TDB2;A0A0C4DGV7;P02753;Q5VY30
12,gsea,Diseases of the neuronal system,0.9818181818181819,1.2787928016728831,0.09647495361781076,0.627098802012526,0.912,2/2,5.26%,TTR;RBP4,A0A087WT59;A0A087WV45;A6XGL1;A6XMH1;E9KL36;P02766;Q53WY6;Q8TDB2;A0A0C4DGV7;P02753;Q5VY30
13,gsea,Retinoid cycle disease events,0.9818181818181819,1.2787928016728831,0.09647495361781076,0.627098802012526,0.912,2/2,5.26%,TTR;RBP4,A0A087WT59;A0A087WV45;A6XGL1;A6XMH1;E9KL36;P02766;Q53WY6;Q8TDB2;A0A0C4DGV7;P02753;Q5VY30
14,gsea,Diseases associated with visual transduction,0.9818181818181819,1.2787928016728831,0.09647495361781076,0.627098802012526,0.912,2/2,5.26%,TTR;RBP4,A0A087WT59;A0A087WV45;A6XGL1;A6XMH1;E9KL36;P02766;Q53WY6;Q8TDB2;A0A0C4DGV7;P02753;Q5VY30
15,gsea,Signal Transduction,0.42984192282263806,1.2667940993380233,0.15775034293552812,0.6914608533482065,0.946,2/6,36.84%,KNG1;ABR,B4DPP8;D3DNU8;P01042-2;P01042-3;Q05CF8;A0A0G2JQ41;B7Z2X0;B7Z683;B7Z7Z1;I3L1U8;I3L379;Q12979;Q12979-2;Q12979-3;Q12979-4;Q6ZT60
16,gsea,Hemostasis,0.7051583014809315,1.265188837368196,0.1574074074074074,0.6580916955620397,0.95,10/11,40.35%,CLEC3B;CLU;SERPIND1;AHSG;APOA1;KNG1;A1BG;A2M;SERPING1;ITIH4,A0A024R2Q7;E9PHK0;P05452;B4DW11;E5RG36;E5RGB0;E5RH61;E5RJZ5;E7ERK6;E7ETB4;H0YAS8;H0YC35;H0YLK8;P10909;P10909-2;P10909-3;P10909-4;P10909-5;Q6LDQ3;Q8IWL5;Q8IWM0;P05546;Q8IVC0;B7Z8Q2;C9JV77;P02765;A0A024R3E3;F8W696;P02647;Q8TDB0;Q9Y355;B4DPP8;D3DNU8;P01042-2;P01042-3;Q05CF8;B3KP79;B3KWB5;M0R009;P04217;P04217-2;Q7Z3U3;V9HWD8;B2R950;B7Z7M2;F8W7L3;H0YFH1;P01023;P20742;P20742-2;Q9BQ22;A0A0S2Z333;E9KL26;E9PGN7;H0YCA1;H9KV48;P05155;P05155-2;P05155-3;Q5UGI6;B2RMS9;B7Z544;B7Z551;B7Z8Q7;B7ZKJ8;H7C0L5;Q14624;Q14624-2;Q14624-3;Q14624-4;Q68DH2
17,gsea,Post-translational protein modification,0.6888710399413378,1.2605686564952745,0.15,0.6473726968855426,0.957,5/7,26.32%,SERPIND1;ITIH2;AHSG;APOA1;KNG1,P05546;Q8IVC0;A0A087WTE1;A2RTY6;B4DM79;D3DRR6;P19823;Q5T985;Q5T987;B7Z8Q2;C9JV77;P02765;A0A024R3E3;F8W696;P02647;Q8TDB0;Q9Y355;B4DPP8;D3DNU8;P01042-2;P01042-3;Q05CF8
18,gsea,Neutrophil degranulation,0.6857517223296968,1.2494169413963458,0.1793478260869565,0.7350202640844101,0.962,4/5,29.82%,TTR;TSPAN14;AHSG;A1BG,A0A087WT59;A0A087WV45;A6XGL1;A6XMH1;E9KL36;P02766;Q53WY6;Q8TDB2;A6NEP9;H7BXY6;Q8N2P5;Q8NG11;Q8NG11-2;Q8NG11-3;B7Z8Q2;C9JV77;P02765;B3KP79;B3KWB5;M0R009;P04217;P04217-2;Q7Z3U3;V9HWD8
19,gsea,Sensory Perception,0.8440993479374984,1.2446209227835623,0.1294559099437148,0.6480647195139141,0.971,2/3,5.26%,TTR;RBP4,A0A087WT59;A0A087WV45;A6XGL1;A6XMH1;E9KL36;P02766;Q53WY6;Q8TDB2;A0A0C4DGV7;P02753;Q5VY30
20,gsea,Metabolism of fat-soluble vitamins,0.8440993479374984,1.2446209227835623,0.1294559099437148,0.6480647195139141,0.971,2/3,5.26%,TTR;RBP4,A0A087WT59;A0A087WV45;A6XGL1;A6XMH1;E9KL36;P02766;Q53WY6;Q8TDB2;A0A0C4DGV7;P02753;Q5VY30
21,gsea,Visual phototransduction,0.8440993479374984,1.2446209227835623,0.1294559099437148,0.6480647195139141,0.971,2/3,5.26%,TTR;RBP4,A0A087WT59;A0A087WV45;A6XGL1;A6XMH1;E9KL36;P02766;Q53WY6;Q8TDB2;A0A0C4DGV7;P02753;Q5VY30
22,gsea,Retinoid metabolism and transport,0.8440993479374984,1.2446209227835623,0.1294559099437148,0.6480647195139141,0.971,2/3,5.26%,TTR;RBP4,A0A087WT59;A0A087WV45;A6XGL1;A6XMH1;E9KL36;P02766;Q53WY6;Q8TDB2;A0A0C4DGV7;P02753;Q5VY30
23,gsea,Regulation of lipid metabolism by PPARalpha,0.5551346210852259,1.2157139140933109,0.19434628975265017,0.7623662286052916,0.995,1/3,24.56%,APOA1,A0A024R3E3;F8W696;P02647;Q8TDB0;Q9Y355
24,gsea,PPARA activates gene expression,0.5551346210852259,1.2157139140933109,0.19434628975265017,0.7623662286052916,0.995,1/3,24.56%,APOA1,A0A024R3E3;F8W696;P02647;Q8TDB0;Q9Y355
25,gsea,Extracellular matrix organization,0.730769230769231,1.2022546530770863,0.23694029850746268,0.831755740338025,0.995,5/5,33.33%,TTR;MFAP4;COL18A1;LUM;A2M,A0A087WT59;A0A087WV45;A6XGL1;A6XMH1;E9KL36;P02766;Q53WY6;Q8TDB2;A0A024QZ34;K7ES70;P55083;P55083-2;D3DSM4;D3DSM5;H7BXV5;H7C457;P39060;P39060-1;P39060-2;Q8NG19;P51884;Q53FV4;B2R950;B7Z7M2;F8W7L3;H0YFH1;P01023;P20742;P20742-2;Q9BQ22
26,gsea,Vesicle-mediated transport,0.5986844832372782,1.1939171819502057,0.20757825370675453,0.854932999719837,0.998,2/3,35.09%,APOA1;HPX,A0A024R3E3;F8W696;P02647;Q8TDB0;Q9Y355;B7Z8Q4;P02790;Q9BS19
27,gsea,Metabolism of amino acids and derivatives,0.6079633911468315,1.1856646977166228,0.27202472952086554,0.8977747511316724,0.998,1/4,19.30%,GATM,A0A024R5Q4;H0YKW9;H0YLC6;H0YMX4;H0YN43;P50440;P50440-2;P50440-3
28,gsea,Molecules associated with elastic fibres,0.9821428571428571,1.1813516533543034,0.20809248554913296,0.8716201299078561,1.0,1/1,3.51%,MFAP4,A0A024QZ34;K7ES70;P55083;P55083-2
29,gsea,Elastic fibre formation,0.9821428571428571,1.1813516533543034,0.20809248554913296,0.8716201299078561,1.0,1/1,3.51%,MFAP4,A0A024QZ34;K7ES70;P55083;P55083-2
30,gsea,Platelet degranulation,0.7083333333333333,1.177771529309303,0.27514231499051234,0.82833027524874,1.0,9/9,40.35%,CLEC3B;CLU;AHSG;APOA1;KNG1;A1BG;A2M;SERPING1;ITIH4,A0A024R2Q7;E9PHK0;P05452;B4DW11;E5RG36;E5RGB0;E5RH61;E5RJZ5;E7ERK6;E7ETB4;H0YAS8;H0YC35;H0YLK8;P10909;P10909-2;P10909-3;P10909-4;P10909-5;Q6LDQ3;Q8IWL5;Q8IWM0;B7Z8Q2;C9JV77;P02765;A0A024R3E3;F8W696;P02647;Q8TDB0;Q9Y355;B4DPP8;D3DNU8;P01042-2;P01042-3;Q05CF8;B3KP79;B3KWB5;M0R009;P04217;P04217-2;Q7Z3U3;V9HWD8;B2R950;B7Z7M2;F8W7L3;H0YFH1;P01023;P20742;P20742-2;Q9BQ22;A0A0S2Z333;E9KL26;E9PGN7;H0YCA1;H9KV48;P05155;P05155-2;P05155-3;Q5UGI6;B2RMS9;B7Z544;B7Z551;B7Z8Q7;B7ZKJ8;H7C0L5;Q14624;Q14624-2;Q14624-3;Q14624-4;Q68DH2
31,gsea,"Platelet activation, signaling and aggregation",0.7083333333333333,1.177771529309303,0.27514231499051234,0.82833027524874,1.0,9/9,40.35%,CLEC3B;CLU;AHSG;APOA1;KNG1;A1BG;A2M;SERPING1;ITIH4,A0A024R2Q7;E9PHK0;P05452;B4DW11;E5RG36;E5RGB0;E5RH61;E5RJZ5;E7ERK6;E7ETB4;H0YAS8;H0YC35;H0YLK8;P10909;P10909-2;P10909-3;P10909-4;P10909-5;Q6LDQ3;Q8IWL5;Q8IWM0;B7Z8Q2;C9JV77;P02765;A0A024R3E3;F8W696;P02647;Q8TDB0;Q9Y355;B4DPP8;D3DNU8;P01042-2;P01042-3;Q05CF8;B3KP79;B3KWB5;M0R009;P04217;P04217-2;Q7Z3U3;V9HWD8;B2R950;B7Z7M2;F8W7L3;H0YFH1;P01023;P20742;P20742-2;Q9BQ22;A0A0S2Z333;E9KL26;E9PGN7;H0YCA1;H9KV48;P05155;P05155-2;P05155-3;Q5UGI6;B2RMS9;B7Z544;B7Z551;B7Z8Q7;B7ZKJ8;H7C0L5;Q14624;Q14624-2;Q14624-3;Q14624-4;Q68DH2
32,gsea,Response to elevated platelet cytosolic Ca2+,0.7083333333333333,1.177771529309303,0.27514231499051234,0.82833027524874,1.0,9/9,40.35%,CLEC3B;CLU;AHSG;APOA1;KNG1;A1BG;A2M;SERPING1;ITIH4,A0A024R2Q7;E9PHK0;P05452;B4DW11;E5RG36;E5RGB0;E5RH61;E5RJZ5;E7ERK6;E7ETB4;H0YAS8;H0YC35;H0YLK8;P10909;P10909-2;P10909-3;P10909-4;P10909-5;Q6LDQ3;Q8IWL5;Q8IWM0;B7Z8Q2;C9JV77;P02765;A0A024R3E3;F8W696;P02647;Q8TDB0;Q9Y355;B4DPP8;D3DNU8;P01042-2;P01042-3;Q05CF8;B3KP79;B3KWB5;M0R009;P04217;P04217-2;Q7Z3U3;V9HWD8;B2R950;B7Z7M2;F8W7L3;H0YFH1;P01023;P20742;P20742-2;Q9BQ22;A0A0S2Z333;E9KL26;E9PGN7;H0YCA1;H9KV48;P05155;P05155-2;P05155-3;Q5UGI6;B2RMS9;B7Z544;B7Z551;B7Z8Q7;B7ZKJ8;H7C0L5;Q14624;Q14624-2;Q14624-3;Q14624-4;Q68DH2
33,gsea,Formation of the cornified envelope,-0.9642857142857142,-1.1708566306713881,0.265748031496063,1.0,0.995,1/1,7.02%,TGM5,A0A024R9P4;A0A024R9T4;A0A087WVS3;A0A087WVW4;A0A087WZC4;A2A299;A2A2A0;B2R7D1;B4DIT7;B4DPS8;B4DTN7;B4DU73;B4YUQ1;B4YUQ2;B4YUQ3;O43548;O43548-2;P21980;P21980-2;P21980-3;P49221;Q0II16;Q6DKH2;Q9H035;V9HWG3
34,gsea,Developmental Biology,-0.9642857142857142,-1.1708566306713881,0.265748031496063,1.0,0.995,1/1,7.02%,TGM5,A0A024R9P4;A0A024R9T4;A0A087WVS3;A0A087WVW4;A0A087WZC4;A2A299;A2A2A0;B2R7D1;B4DIT7;B4DPS8;B4DTN7;B4DU73;B4YUQ1;B4YUQ2;B4YUQ3;O43548;O43548-2;P21980;P21980-2;P21980-3;P49221;Q0II16;Q6DKH2;Q9H035;V9HWG3
35,gsea,Keratinization,-0.9642857142857142,-1.1708566306713881,0.265748031496063,1.0,0.995,1/1,7.02%,TGM5,A0A024R9P4;A0A024R9T4;A0A087WVS3;A0A087WVW4;A0A087WZC4;A2A299;A2A2A0;B2R7D1;B4DIT7;B4DPS8;B4DTN7;B4DU73;B4YUQ1;B4YUQ2;B4YUQ3;O43548;O43548-2;P21980;P21980-2;P21980-3;P49221;Q0II16;Q6DKH2;Q9H035;V9HWG3
36,gsea,Post-translational protein phosphorylation,0.7103896191631052,1.1669219767794743,0.3016759776536313,0.8364291441120666,1.0,5/6,26.32%,SERPIND1;ITIH2;AHSG;APOA1;KNG1,P05546;Q8IVC0;A0A087WTE1;A2RTY6;B4DM79;D3DRR6;P19823;Q5T985;Q5T987;B7Z8Q2;C9JV77;P02765;A0A024R3E3;F8W696;P02647;Q8TDB0;Q9Y355;B4DPP8;D3DNU8;P01042-2;P01042-3;Q05CF8
37,gsea,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.7103896191631052,1.1669219767794743,0.3016759776536313,0.8364291441120666,1.0,5/6,26.32%,SERPIND1;ITIH2;AHSG;APOA1;KNG1,P05546;Q8IVC0;A0A087WTE1;A2RTY6;B4DM79;D3DRR6;P19823;Q5T985;Q5T987;B7Z8Q2;C9JV77;P02765;A0A024R3E3;F8W696;P02647;Q8TDB0;Q9Y355;B4DPP8;D3DNU8;P01042-2;P01042-3;Q05CF8
38,gsea,Non-integrin membrane-ECM interactions,1.0,1.1665739047467598,0.2786259541984733,0.826599979471925,1.0,1/1,1.75%,TTR,A0A087WT59;A0A087WV45;A6XGL1;A6XMH1;E9KL36;P02766;Q53WY6;Q8TDB2
39,gsea,Viral Infection Pathways,-0.7454545454545454,-1.1444839932337931,0.3225806451612903,1.0,1.0,2/2,29.82%,ATP6V1H;ATP1A1,A0A024R7U9;A0A024R7X3;A0A0D9SG68;B3KUZ7;B4E054;E5RG49;E5RHH0;E5RJG1;E5RK31;G3V126;Q8TF11;Q9UI12;Q9UI12-2;B7Z1N5;B7Z3V1;P05023;P05023-2;P05023-3;P05023-4;Q58I23;Q5TC01;Q5TC02
40,gsea,Retinoid metabolism disease events,0.9642857142857143,1.1356166612430858,0.23404255319148937,0.98020315257217,1.0,1/1,5.26%,RBP4,A0A0C4DGV7;P02753;Q5VY30
41,gsea,Formation of the Editosome,-0.9464285714285714,-1.1340210339686516,0.3935969868173258,1.0,1.0,1/1,8.77%,APOBEC2,B4DUL0;Q9Y235
42,gsea,mRNA Editing,-0.9464285714285714,-1.1340210339686516,0.3935969868173258,1.0,1.0,1/1,8.77%,APOBEC2,B4DUL0;Q9Y235
43,gsea,mRNA Editing: C to U Conversion,-0.9464285714285714,-1.1340210339686516,0.3935969868173258,1.0,1.0,1/1,8.77%,APOBEC2,B4DUL0;Q9Y235
44,gsea,RHOBTB GTPase Cycle,-0.9107142857142857,-1.1156645438756099,0.42722117202268434,1.0,1.0,1/1,12.28%,TMOD3,H0YKU1;H0YNJ8;P28289;P28289-2;Q5HYL6;Q9NYL9;Q9NZQ9;Q9NZQ9-2
45,gsea,RND3 GTPase cycle,-0.9107142857142857,-1.1156645438756099,0.42722117202268434,1.0,1.0,1/1,12.28%,TMOD3,H0YKU1;H0YNJ8;P28289;P28289-2;Q5HYL6;Q9NYL9;Q9NZQ9;Q9NZQ9-2
46,gsea,RHOBTB2 GTPase cycle,-0.9107142857142857,-1.1156645438756099,0.42722117202268434,1.0,1.0,1/1,12.28%,TMOD3,H0YKU1;H0YNJ8;P28289;P28289-2;Q5HYL6;Q9NYL9;Q9NZQ9;Q9NZQ9-2
47,gsea,Integrin cell surface interactions,0.7454545454545454,1.1141568112030389,0.32899628252788105,1.0,1.0,2/2,28.07%,COL18A1;LUM,D3DSM4;D3DSM5;H7BXV5;H7C457;P39060;P39060-1;P39060-2;Q8NG19;P51884;Q53FV4
48,gsea,Striated Muscle Contraction,-0.9259259259259258,-1.1131922864075594,0.4321223709369025,1.0,1.0,3/3,14.04%,TMOD1;TMOD3;TMOD4,H0YKU1;H0YNJ8;P28289;P28289-2;Q5HYL6;Q9NYL9;Q9NZQ9;Q9NZQ9-2;H0YKU1;H0YNJ8;P28289;P28289-2;Q5HYL6;Q9NYL9;Q9NZQ9;Q9NZQ9-2;H0YKU1;H0YNJ8;P28289;P28289-2;Q5HYL6;Q9NYL9;Q9NZQ9;Q9NZQ9-2
49,gsea,Formation of Fibrin Clot (Clotting Cascade),0.6603773584905661,1.1110732720729763,0.3883677298311445,1.0,1.0,4/4,38.60%,SERPIND1;KNG1;A2M;SERPING1,P05546;Q8IVC0;B4DPP8;D3DNU8;P01042-2;P01042-3;Q05CF8;B2R950;B7Z7M2;F8W7L3;H0YFH1;P01023;P20742;P20742-2;Q9BQ22;A0A0S2Z333;E9KL26;E9PGN7;H0YCA1;H9KV48;P05155;P05155-2;P05155-3;Q5UGI6
50,gsea,Intrinsic Pathway of Fibrin Clot Formation,0.6603773584905661,1.1110732720729763,0.3883677298311445,1.0,1.0,4/4,38.60%,SERPIND1;KNG1;A2M;SERPING1,P05546;Q8IVC0;B4DPP8;D3DNU8;P01042-2;P01042-3;Q05CF8;B2R950;B7Z7M2;F8W7L3;H0YFH1;P01023;P20742;P20742-2;Q9BQ22;A0A0S2Z333;E9KL26;E9PGN7;H0YCA1;H9KV48;P05155;P05155-2;P05155-3;Q5UGI6
51,gsea,Degradation of the extracellular matrix,0.6909090909090907,1.1027445864186651,0.41712204007285975,1.0,1.0,2/2,33.33%,COL18A1;A2M,D3DSM4;D3DSM5;H7BXV5;H7C457;P39060;P39060-1;P39060-2;Q8NG19;B2R950;B7Z7M2;F8W7L3;H0YFH1;P01023;P20742;P20742-2;Q9BQ22
52,gsea,Metabolism of RNA,-0.6545454545454545,-1.1004471028125158,0.3592436974789916,1.0,1.0,2/2,38.60%,APOBEC2;EPRS1,B4DUL0;Q9Y235;B4DKX5;B4DP50;H6WCP5;P07814;Q3KQZ8;V9GYZ6;V9GZ76
53,gsea,Alanine metabolism,-0.8181818181818181,-1.093333967287943,0.3776908023483366,1.0,1.0,2/2,22.81%,GPT;GPT2,A0A024R6R2;B3KR40;B4DPT5;B4E1C6;P24298;Q8TD30;Q8TD30-2;A0A024R6R2;B3KR40;B4DPT5;B4E1C6;P24298;Q8TD30;Q8TD30-2
54,gsea,Suppression of phagosomal maturation,-0.8571428571428571,-1.091051600261267,0.4674329501915709,1.0,1.0,1/1,17.54%,ATP6V1H,A0A024R7U9;A0A024R7X3;A0A0D9SG68;B3KUZ7;B4E054;E5RG49;E5RHH0;E5RJG1;E5RK31;G3V126;Q8TF11;Q9UI12;Q9UI12-2
55,gsea,Amino acids regulate mTORC1,-0.8571428571428571,-1.091051600261267,0.4674329501915709,1.0,1.0,1/1,17.54%,ATP6V1H,A0A024R7U9;A0A024R7X3;A0A0D9SG68;B3KUZ7;B4E054;E5RG49;E5RHH0;E5RJG1;E5RK31;G3V126;Q8TF11;Q9UI12;Q9UI12-2
56,gsea,The role of Nef in HIV-1 replication and disease pathogenesis,-0.8571428571428571,-1.091051600261267,0.4674329501915709,1.0,1.0,1/1,17.54%,ATP6V1H,A0A024R7U9;A0A024R7X3;A0A0D9SG68;B3KUZ7;B4E054;E5RG49;E5RHH0;E5RJG1;E5RK31;G3V126;Q8TF11;Q9UI12;Q9UI12-2
57,gsea,ROS and RNS production in phagocytes,-0.8571428571428571,-1.091051600261267,0.4674329501915709,1.0,1.0,1/1,17.54%,ATP6V1H,A0A024R7U9;A0A024R7X3;A0A0D9SG68;B3KUZ7;B4E054;E5RG49;E5RHH0;E5RJG1;E5RK31;G3V126;Q8TF11;Q9UI12;Q9UI12-2
58,gsea,Signaling by Receptor Tyrosine Kinases,-0.8571428571428571,-1.091051600261267,0.4674329501915709,1.0,1.0,1/1,17.54%,ATP6V1H,A0A024R7U9;A0A024R7X3;A0A0D9SG68;B3KUZ7;B4E054;E5RG49;E5RHH0;E5RJG1;E5RK31;G3V126;Q8TF11;Q9UI12;Q9UI12-2
59,gsea,Blockage of phagosome acidification,-0.8571428571428571,-1.091051600261267,0.4674329501915709,1.0,1.0,1/1,17.54%,ATP6V1H,A0A024R7U9;A0A024R7X3;A0A0D9SG68;B3KUZ7;B4E054;E5RG49;E5RHH0;E5RJG1;E5RK31;G3V126;Q8TF11;Q9UI12;Q9UI12-2
60,gsea,Host Interactions of HIV factors,-0.8571428571428571,-1.091051600261267,0.4674329501915709,1.0,1.0,1/1,17.54%,ATP6V1H,A0A024R7U9;A0A024R7X3;A0A0D9SG68;B3KUZ7;B4E054;E5RG49;E5RHH0;E5RJG1;E5RK31;G3V126;Q8TF11;Q9UI12;Q9UI12-2
61,gsea,Nef-mediates down modulation of cell surface receptors by recruiting them to clathrin adapters,-0.8571428571428571,-1.091051600261267,0.4674329501915709,1.0,1.0,1/1,17.54%,ATP6V1H,A0A024R7U9;A0A024R7X3;A0A0D9SG68;B3KUZ7;B4E054;E5RG49;E5RHH0;E5RJG1;E5RK31;G3V126;Q8TF11;Q9UI12;Q9UI12-2
62,gsea,Infection with Mycobacterium tuberculosis,-0.8571428571428571,-1.091051600261267,0.4674329501915709,1.0,1.0,1/1,17.54%,ATP6V1H,A0A024R7U9;A0A024R7X3;A0A0D9SG68;B3KUZ7;B4E054;E5RG49;E5RHH0;E5RJG1;E5RK31;G3V126;Q8TF11;Q9UI12;Q9UI12-2
63,gsea,Insulin receptor recycling,-0.8571428571428571,-1.091051600261267,0.4674329501915709,1.0,1.0,1/1,17.54%,ATP6V1H,A0A024R7U9;A0A024R7X3;A0A0D9SG68;B3KUZ7;B4E054;E5RG49;E5RHH0;E5RJG1;E5RK31;G3V126;Q8TF11;Q9UI12;Q9UI12-2
64,gsea,Signaling by Insulin receptor,-0.8571428571428571,-1.091051600261267,0.4674329501915709,1.0,1.0,1/1,17.54%,ATP6V1H,A0A024R7U9;A0A024R7X3;A0A0D9SG68;B3KUZ7;B4E054;E5RG49;E5RHH0;E5RJG1;E5RK31;G3V126;Q8TF11;Q9UI12;Q9UI12-2
65,gsea,Transferrin endocytosis and recycling,-0.8571428571428571,-1.091051600261267,0.4674329501915709,1.0,1.0,1/1,17.54%,ATP6V1H,A0A024R7U9;A0A024R7X3;A0A0D9SG68;B3KUZ7;B4E054;E5RG49;E5RHH0;E5RJG1;E5RK31;G3V126;Q8TF11;Q9UI12;Q9UI12-2
66,gsea,Bacterial Infection Pathways,-0.8571428571428571,-1.091051600261267,0.4674329501915709,1.0,1.0,1/1,17.54%,ATP6V1H,A0A024R7U9;A0A024R7X3;A0A0D9SG68;B3KUZ7;B4E054;E5RG49;E5RHH0;E5RJG1;E5RK31;G3V126;Q8TF11;Q9UI12;Q9UI12-2
67,gsea,Nef Mediated CD8 Down-regulation,-0.8571428571428571,-1.091051600261267,0.4674329501915709,1.0,1.0,1/1,17.54%,ATP6V1H,A0A024R7U9;A0A024R7X3;A0A0D9SG68;B3KUZ7;B4E054;E5RG49;E5RHH0;E5RJG1;E5RK31;G3V126;Q8TF11;Q9UI12;Q9UI12-2
68,gsea,Nef Mediated CD4 Down-regulation,-0.8571428571428571,-1.091051600261267,0.4674329501915709,1.0,1.0,1/1,17.54%,ATP6V1H,A0A024R7U9;A0A024R7X3;A0A0D9SG68;B3KUZ7;B4E054;E5RG49;E5RHH0;E5RJG1;E5RK31;G3V126;Q8TF11;Q9UI12;Q9UI12-2
69,gsea,HIV Infection,-0.8571428571428571,-1.091051600261267,0.4674329501915709,1.0,1.0,1/1,17.54%,ATP6V1H,A0A024R7U9;A0A024R7X3;A0A0D9SG68;B3KUZ7;B4E054;E5RG49;E5RHH0;E5RJG1;E5RK31;G3V126;Q8TF11;Q9UI12;Q9UI12-2
70,gsea,Cellular response to starvation,-0.8571428571428571,-1.091051600261267,0.4674329501915709,1.0,1.0,1/1,17.54%,ATP6V1H,A0A024R7U9;A0A024R7X3;A0A0D9SG68;B3KUZ7;B4E054;E5RG49;E5RHH0;E5RJG1;E5RK31;G3V126;Q8TF11;Q9UI12;Q9UI12-2
71,gsea,Response of Mtb to phagocytosis,-0.8571428571428571,-1.091051600261267,0.4674329501915709,1.0,1.0,1/1,17.54%,ATP6V1H,A0A024R7U9;A0A024R7X3;A0A0D9SG68;B3KUZ7;B4E054;E5RG49;E5RHH0;E5RJG1;E5RK31;G3V126;Q8TF11;Q9UI12;Q9UI12-2
72,gsea,Ketone body metabolism,-0.8392857142857142,-1.0837705568537541,0.47609942638623326,1.0,1.0,1/1,19.30%,ACSS3,A0A0B4J1R2;F8VZB4;Q9H6R3;Q9H6R3-2
73,gsea,Synthesis of Ketone Bodies,-0.8392857142857142,-1.0837705568537541,0.47609942638623326,1.0,1.0,1/1,19.30%,ACSS3,A0A0B4J1R2;F8VZB4;Q9H6R3;Q9H6R3-2
74,gsea,GPCR downstream signalling,0.6545454545454545,1.079010812130318,0.30866425992779783,1.0,1.0,2/2,36.84%,KNG1;ABR,B4DPP8;D3DNU8;P01042-2;P01042-3;Q05CF8;A0A0G2JQ41;B7Z2X0;B7Z683;B7Z7Z1;I3L1U8;I3L379;Q12979;Q12979-2;Q12979-3;Q12979-4;Q6ZT60
75,gsea,Signaling by GPCR,0.6545454545454545,1.079010812130318,0.30866425992779783,1.0,1.0,2/2,36.84%,KNG1;ABR,B4DPP8;D3DNU8;P01042-2;P01042-3;Q05CF8;A0A0G2JQ41;B7Z2X0;B7Z683;B7Z7Z1;I3L1U8;I3L379;Q12979;Q12979-2;Q12979-3;Q12979-4;Q6ZT60
76,gsea,Translation,-0.6545454545454545,-1.0785114692147058,0.33537832310838445,1.0,1.0,2/2,38.60%,PTCD3;EPRS1,B2RDU4;B4DF73;B8ZZQ4;F8WE76;Q96EY7;Q96EY7-2;B4DKX5;B4DP50;H6WCP5;P07814;Q3KQZ8;V9GYZ6;V9GZ76
77,gsea,Laminin interactions,0.8571428571428572,1.0770989457640023,0.360377358490566,0.9711716108341757,1.0,1/1,15.79%,COL18A1,D3DSM4;D3DSM5;H7BXV5;H7C457;P39060;P39060-1;P39060-2;Q8NG19
78,gsea,Assembly of collagen fibrils and other multimeric structures,0.8571428571428572,1.0770989457640023,0.360377358490566,0.9711716108341757,1.0,1/1,15.79%,COL18A1,D3DSM4;D3DSM5;H7BXV5;H7C457;P39060;P39060-1;P39060-2;Q8NG19
79,gsea,Collagen biosynthesis and modifying enzymes,0.8571428571428572,1.0770989457640023,0.360377358490566,0.9711716108341757,1.0,1/1,15.79%,COL18A1,D3DSM4;D3DSM5;H7BXV5;H7C457;P39060;P39060-1;P39060-2;Q8NG19
80,gsea,Activation of Matrix Metalloproteinases,0.8571428571428572,1.0770989457640023,0.360377358490566,0.9711716108341757,1.0,1/1,15.79%,COL18A1,D3DSM4;D3DSM5;H7BXV5;H7C457;P39060;P39060-1;P39060-2;Q8NG19
81,gsea,Collagen chain trimerization,0.8571428571428572,1.0770989457640023,0.360377358490566,0.9711716108341757,1.0,1/1,15.79%,COL18A1,D3DSM4;D3DSM5;H7BXV5;H7C457;P39060;P39060-1;P39060-2;Q8NG19
82,gsea,Collagen degradation,0.8571428571428572,1.0770989457640023,0.360377358490566,0.9711716108341757,1.0,1/1,15.79%,COL18A1,D3DSM4;D3DSM5;H7BXV5;H7C457;P39060;P39060-1;P39060-2;Q8NG19
83,gsea,Collagen formation,0.8571428571428572,1.0770989457640023,0.360377358490566,0.9711716108341757,1.0,1/1,15.79%,COL18A1,D3DSM4;D3DSM5;H7BXV5;H7C457;P39060;P39060-1;P39060-2;Q8NG19
84,gsea,Common Pathway of Fibrin Clot Formation,0.875,1.0750672494956288,0.421455938697318,0.9619544823541716,1.0,1/1,14.04%,SERPIND1,P05546;Q8IVC0
85,gsea,Protein localization,-0.7678571428571428,-1.0698545092649618,0.38285714285714284,1.0,1.0,1/1,26.32%,CHCHD4,A0A024R2F8;A0A024R2I5;Q8N4Q1;Q8N4Q1-2
86,gsea,Mitochondrial protein import,-0.7678571428571428,-1.0698545092649618,0.38285714285714284,1.0,1.0,1/1,26.32%,CHCHD4,A0A024R2F8;A0A024R2I5;Q8N4Q1;Q8N4Q1-2
87,gsea,Circadian Clock,-0.6,-1.0693137166423579,0.36796536796536794,1.0,1.0,2/2,43.86%,NAMPT;CPT1A,A0A024R718;A0A0C4DFS8;B7Z8W6;C9JF35;C9JG65;P43490;Q658Z1;A0A024R5F4;B2RAQ8;P50416;P50416-2
88,gsea,"Plasma lipoprotein assembly, remodeling, and clearance",0.6909090909090909,1.0673324596652747,0.4130019120458891,0.9406683760485134,1.0,2/2,33.33%,APOA1;A2M,A0A024R3E3;F8W696;P02647;Q8TDB0;Q9Y355;B2R950;B7Z7M2;F8W7L3;H0YFH1;P01023;P20742;P20742-2;Q9BQ22
89,gsea,Plasma lipoprotein assembly,0.6909090909090909,1.0673324596652747,0.4130019120458891,0.9406683760485134,1.0,2/2,33.33%,APOA1;A2M,A0A024R3E3;F8W696;P02647;Q8TDB0;Q9Y355;B2R950;B7Z7M2;F8W7L3;H0YFH1;P01023;P20742;P20742-2;Q9BQ22
90,gsea,HDL assembly,0.6909090909090909,1.0673324596652747,0.4130019120458891,0.9406683760485134,1.0,2/2,33.33%,APOA1;A2M,A0A024R3E3;F8W696;P02647;Q8TDB0;Q9Y355;B2R950;B7Z7M2;F8W7L3;H0YFH1;P01023;P20742;P20742-2;Q9BQ22
91,gsea,Terminal pathway of complement,0.8928571428571429,1.06352162218084,0.49221789883268485,0.913959284693415,1.0,1/1,12.28%,CLU,B4DW11;E5RG36;E5RGB0;E5RH61;E5RJZ5;E7ERK6;E7ETB4;H0YAS8;H0YC35;H0YLK8;P10909;P10909-2;P10909-3;P10909-4;P10909-5;Q6LDQ3;Q8IWL5;Q8IWM0
92,gsea,Antimicrobial peptides,0.8928571428571429,1.06352162218084,0.49221789883268485,0.913959284693415,1.0,1/1,12.28%,CLU,B4DW11;E5RG36;E5RGB0;E5RH61;E5RJZ5;E7ERK6;E7ETB4;H0YAS8;H0YC35;H0YLK8;P10909;P10909-2;P10909-3;P10909-4;P10909-5;Q6LDQ3;Q8IWL5;Q8IWM0
93,gsea,Metabolism of nitric oxide: NOS3 activation and regulation,0.8035714285714286,1.0420585864015057,0.42940038684719534,0.957063484240729,1.0,1/1,21.05%,DDAH1,B1AKK2;B4DYP1;B4E3V1;O94760;O94760-2
94,gsea,eNOS activation,0.8035714285714286,1.0420585864015057,0.42940038684719534,0.957063484240729,1.0,1/1,21.05%,DDAH1,B1AKK2;B4DYP1;B4E3V1;O94760;O94760-2
95,gsea,Gene expression (Transcription),-0.6181818181818182,-1.03641537397959,0.40124740124740127,1.0,1.0,2/2,42.11%,NAMPT;NDUFA4,A0A024R718;A0A0C4DFS8;B7Z8W6;C9JF35;C9JG65;P43490;Q658Z1;A0A024R9Z0;O00483
96,gsea,RNA Polymerase II Transcription,-0.6181818181818182,-1.03641537397959,0.40124740124740127,1.0,1.0,2/2,42.11%,NAMPT;NDUFA4,A0A024R718;A0A0C4DFS8;B7Z8W6;C9JF35;C9JG65;P43490;Q658Z1;A0A024R9Z0;O00483
97,gsea,Generic Transcription Pathway,-0.6181818181818182,-1.03641537397959,0.40124740124740127,1.0,1.0,2/2,42.11%,NAMPT;NDUFA4,A0A024R718;A0A0C4DFS8;B7Z8W6;C9JF35;C9JG65;P43490;Q658Z1;A0A024R9Z0;O00483
98,gsea,Defective ST3GAL3 causes MCT12 and EIEE15,0.7454545454545456,1.0340913065053463,0.4461839530332681,0.8382178646199651,1.0,2/2,28.07%,PRELP;LUM,P51888;Q6FHG6;Q7Z4B2;P51884;Q53FV4
99,gsea,Keratan sulfate/keratin metabolism,0.7454545454545456,1.0340913065053463,0.4461839530332681,0.8382178646199651,1.0,2/2,28.07%,PRELP;LUM,P51888;Q6FHG6;Q7Z4B2;P51884;Q53FV4
100,gsea,Defective B4GALT1 causes B4GALT1-CDG (CDG-2d),0.7454545454545456,1.0340913065053463,0.4461839530332681,0.8382178646199651,1.0,2/2,28.07%,PRELP;LUM,P51888;Q6FHG6;Q7Z4B2;P51884;Q53FV4
101,gsea,Glycosaminoglycan metabolism,0.7454545454545456,1.0340913065053463,0.4461839530332681,0.8382178646199651,1.0,2/2,28.07%,PRELP;LUM,P51888;Q6FHG6;Q7Z4B2;P51884;Q53FV4
102,gsea,Diseases associated with glycosaminoglycan metabolism,0.7454545454545456,1.0340913065053463,0.4461839530332681,0.8382178646199651,1.0,2/2,28.07%,PRELP;LUM,P51888;Q6FHG6;Q7Z4B2;P51884;Q53FV4
103,gsea,Keratan sulfate biosynthesis,0.7454545454545456,1.0340913065053463,0.4461839530332681,0.8382178646199651,1.0,2/2,28.07%,PRELP;LUM,P51888;Q6FHG6;Q7Z4B2;P51884;Q53FV4
104,gsea,Keratan sulfate degradation,0.7454545454545456,1.0340913065053463,0.4461839530332681,0.8382178646199651,1.0,2/2,28.07%,PRELP;LUM,P51888;Q6FHG6;Q7Z4B2;P51884;Q53FV4
105,gsea,Defective CHST6 causes MCDC1,0.7454545454545456,1.0340913065053463,0.4461839530332681,0.8382178646199651,1.0,2/2,28.07%,PRELP;LUM,P51888;Q6FHG6;Q7Z4B2;P51884;Q53FV4
106,gsea,Diseases of metabolism,0.7454545454545456,1.0340913065053463,0.4461839530332681,0.8382178646199651,1.0,2/2,28.07%,PRELP;LUM,P51888;Q6FHG6;Q7Z4B2;P51884;Q53FV4
107,gsea,Diseases of glycosylation,0.7454545454545456,1.0340913065053463,0.4461839530332681,0.8382178646199651,1.0,2/2,28.07%,PRELP;LUM,P51888;Q6FHG6;Q7Z4B2;P51884;Q53FV4
108,gsea,Creatine metabolism,0.8214285714285714,1.0296143250688705,0.4980769230769231,0.844178143611988,1.0,1/1,19.30%,GATM,A0A024R5Q4;H0YKW9;H0YLC6;H0YMX4;H0YN43;P50440;P50440-2;P50440-3
109,gsea,Disorders of transmembrane transporters,0.6,1.0205589934232389,0.4490909090909091,0.8504505525150765,1.0,2/2,42.11%,APOA1;CP,A0A024R3E3;F8W696;P02647;Q8TDB0;Q9Y355;A5PL27;A8K5A4;B3KTA8;B7Z5Q2;D6RE86;H7C5N5;P00450;Q1L857;Q6NSB2
110,gsea,ABC-family proteins mediated transport,0.7678571428571429,1.01311001213026,0.5247524752475248,0.7316976624733675,1.0,1/1,24.56%,APOA1,A0A024R3E3;F8W696;P02647;Q8TDB0;Q9Y355
111,gsea,HDL clearance,0.7678571428571429,1.01311001213026,0.5247524752475248,0.7316976624733675,1.0,1/1,24.56%,APOA1,A0A024R3E3;F8W696;P02647;Q8TDB0;Q9Y355
112,gsea,Scavenging by Class B Receptors,0.7678571428571429,1.01311001213026,0.5247524752475248,0.7316976624733675,1.0,1/1,24.56%,APOA1,A0A024R3E3;F8W696;P02647;Q8TDB0;Q9Y355
113,gsea,Chylomicron remodeling,0.7678571428571429,1.01311001213026,0.5247524752475248,0.7316976624733675,1.0,1/1,24.56%,APOA1,A0A024R3E3;F8W696;P02647;Q8TDB0;Q9Y355
114,gsea,Plasma lipoprotein clearance,0.7678571428571429,1.01311001213026,0.5247524752475248,0.7316976624733675,1.0,1/1,24.56%,APOA1,A0A024R3E3;F8W696;P02647;Q8TDB0;Q9Y355
115,gsea,ABC transporters in lipid homeostasis,0.7678571428571429,1.01311001213026,0.5247524752475248,0.7316976624733675,1.0,1/1,24.56%,APOA1,A0A024R3E3;F8W696;P02647;Q8TDB0;Q9Y355
116,gsea,Chylomicron assembly,0.7678571428571429,1.01311001213026,0.5247524752475248,0.7316976624733675,1.0,1/1,24.56%,APOA1,A0A024R3E3;F8W696;P02647;Q8TDB0;Q9Y355
117,gsea,Defective ABCA1 causes TGD,0.7678571428571429,1.01311001213026,0.5247524752475248,0.7316976624733675,1.0,1/1,24.56%,APOA1,A0A024R3E3;F8W696;P02647;Q8TDB0;Q9Y355
118,gsea,Scavenging by Class A Receptors,0.7678571428571429,1.01311001213026,0.5247524752475248,0.7316976624733675,1.0,1/1,24.56%,APOA1,A0A024R3E3;F8W696;P02647;Q8TDB0;Q9Y355
119,gsea,ABC transporter disorders,0.7678571428571429,1.01311001213026,0.5247524752475248,0.7316976624733675,1.0,1/1,24.56%,APOA1,A0A024R3E3;F8W696;P02647;Q8TDB0;Q9Y355
120,gsea,Plasma lipoprotein remodeling,0.7678571428571429,1.01311001213026,0.5247524752475248,0.7316976624733675,1.0,1/1,24.56%,APOA1,A0A024R3E3;F8W696;P02647;Q8TDB0;Q9Y355
121,gsea,Heme signaling,0.7678571428571429,1.01311001213026,0.5247524752475248,0.7316976624733675,1.0,1/1,24.56%,APOA1,A0A024R3E3;F8W696;P02647;Q8TDB0;Q9Y355
122,gsea,HDL remodeling,0.7678571428571429,1.01311001213026,0.5247524752475248,0.7316976624733675,1.0,1/1,24.56%,APOA1,A0A024R3E3;F8W696;P02647;Q8TDB0;Q9Y355
123,gsea,Regulation of Complement cascade,0.6363636363636365,1.0129747091407195,0.47504621072088726,0.7169034344312549,1.0,2/2,38.60%,CLU;SERPING1,B4DW11;E5RG36;E5RGB0;E5RH61;E5RJZ5;E7ERK6;E7ETB4;H0YAS8;H0YC35;H0YLK8;P10909;P10909-2;P10909-3;P10909-4;P10909-5;Q6LDQ3;Q8IWL5;Q8IWM0;A0A0S2Z333;E9KL26;E9PGN7;H0YCA1;H9KV48;P05155;P05155-2;P05155-3;Q5UGI6
124,gsea,Complement cascade,0.6363636363636365,1.0129747091407195,0.47504621072088726,0.7169034344312549,1.0,2/2,38.60%,CLU;SERPING1,B4DW11;E5RG36;E5RGB0;E5RH61;E5RJZ5;E7ERK6;E7ETB4;H0YAS8;H0YC35;H0YLK8;P10909;P10909-2;P10909-3;P10909-4;P10909-5;Q6LDQ3;Q8IWL5;Q8IWM0;A0A0S2Z333;E9KL26;E9PGN7;H0YCA1;H9KV48;P05155;P05155-2;P05155-3;Q5UGI6
125,gsea,Scavenging of heme from plasma,0.6727272727272728,1.0115389569479094,0.5075757575757576,0.7021132564752588,1.0,2/2,35.09%,APOA1;HPX,A0A024R3E3;F8W696;P02647;Q8TDB0;Q9Y355;B7Z8Q4;P02790;Q9BS19
126,gsea,Binding and Uptake of Ligands by Scavenger Receptors,0.6727272727272728,1.0115389569479094,0.5075757575757576,0.7021132564752588,1.0,2/2,35.09%,APOA1;HPX,A0A024R3E3;F8W696;P02647;Q8TDB0;Q9Y355;B7Z8Q4;P02790;Q9BS19
127,gsea,G alpha (q) signalling events,0.7499999999999999,1.0101391181325157,0.5411764705882353,0.6692358756655415,1.0,1/1,26.32%,KNG1,B4DPP8;D3DNU8;P01042-2;P01042-3;Q05CF8
128,gsea,Peptide ligand-binding receptors,0.7499999999999999,1.0101391181325157,0.5411764705882353,0.6692358756655415,1.0,1/1,26.32%,KNG1,B4DPP8;D3DNU8;P01042-2;P01042-3;Q05CF8
129,gsea,Class A/1 (Rhodopsin-like receptors),0.7499999999999999,1.0101391181325157,0.5411764705882353,0.6692358756655415,1.0,1/1,26.32%,KNG1,B4DPP8;D3DNU8;P01042-2;P01042-3;Q05CF8
130,gsea,G alpha (i) signalling events,0.7499999999999999,1.0101391181325157,0.5411764705882353,0.6692358756655415,1.0,1/1,26.32%,KNG1,B4DPP8;D3DNU8;P01042-2;P01042-3;Q05CF8
131,gsea,GPCR ligand binding,0.7499999999999999,1.0101391181325157,0.5411764705882353,0.6692358756655415,1.0,1/1,26.32%,KNG1,B4DPP8;D3DNU8;P01042-2;P01042-3;Q05CF8
132,gsea,Infectious disease,-0.5740740740740741,-1.0036823077242345,0.4594059405940594,1.0,1.0,3/3,47.37%,ATP6V1H;ATP1A1;SUGT1,A0A024R7U9;A0A024R7X3;A0A0D9SG68;B3KUZ7;B4E054;E5RG49;E5RHH0;E5RJG1;E5RK31;G3V126;Q8TF11;Q9UI12;Q9UI12-2;B7Z1N5;B7Z3V1;P05023;P05023-2;P05023-3;P05023-4;Q58I23;Q5TC01;Q5TC02;A8K5T7;A8K7W3;B4DYC6;Q9P1S2;Q9Y2Z0;Q9Y2Z0-2
133,gsea,ECM proteoglycans,0.7321428571428572,0.9832779052883035,0.53125,0.7300242026379639,1.0,1/1,28.07%,LUM,P51884;Q53FV4
134,gsea,Potential therapeutics for SARS,-0.7321428571428571,-0.9805137289636842,0.5611111111111111,1.0,1.0,1/1,29.82%,ATP1A1,B7Z1N5;B7Z3V1;P05023;P05023-2;P05023-3;P05023-4;Q58I23;Q5TC01;Q5TC02
135,gsea,SARS-CoV Infections,-0.7321428571428571,-0.9805137289636842,0.5611111111111111,1.0,1.0,1/1,29.82%,ATP1A1,B7Z1N5;B7Z3V1;P05023;P05023-2;P05023-3;P05023-4;Q58I23;Q5TC01;Q5TC02
136,gsea,"BMAL1:CLOCK,NPAS2 activates circadian gene expression",-0.6964285714285714,-0.9679835511822585,0.5305719921104537,1.0,1.0,1/1,33.33%,NAMPT,A0A024R718;A0A0C4DFS8;B7Z8W6;C9JF35;C9JG65;P43490;Q658Z1
137,gsea,Metabolism of water-soluble vitamins and cofactors,-0.6964285714285714,-0.9679835511822585,0.5305719921104537,1.0,1.0,1/1,33.33%,NAMPT,A0A024R718;A0A0C4DFS8;B7Z8W6;C9JF35;C9JG65;P43490;Q658Z1
138,gsea,NPAS4 regulates expression of target genes,-0.6964285714285714,-0.9679835511822585,0.5305719921104537,1.0,1.0,1/1,33.33%,NAMPT,A0A024R718;A0A0C4DFS8;B7Z8W6;C9JF35;C9JG65;P43490;Q658Z1
139,gsea,Nicotinamide salvaging,-0.6964285714285714,-0.9679835511822585,0.5305719921104537,1.0,1.0,1/1,33.33%,NAMPT,A0A024R718;A0A0C4DFS8;B7Z8W6;C9JF35;C9JG65;P43490;Q658Z1
140,gsea,Transcriptional Regulation by NPAS4,-0.6964285714285714,-0.9679835511822585,0.5305719921104537,1.0,1.0,1/1,33.33%,NAMPT,A0A024R718;A0A0C4DFS8;B7Z8W6;C9JF35;C9JG65;P43490;Q658Z1
141,gsea,Nicotinate metabolism,-0.6964285714285714,-0.9679835511822585,0.5305719921104537,1.0,1.0,1/1,33.33%,NAMPT,A0A024R718;A0A0C4DFS8;B7Z8W6;C9JF35;C9JG65;P43490;Q658Z1
142,gsea,Mitochondrial translation initiation,-0.6785714285714285,-0.9652382520344321,0.5277777777777778,1.0,1.0,1/1,35.09%,PTCD3,B2RDU4;B4DF73;B8ZZQ4;F8WE76;Q96EY7;Q96EY7-2
143,gsea,Mitochondrial translation,-0.6785714285714285,-0.9652382520344321,0.5277777777777778,1.0,1.0,1/1,35.09%,PTCD3,B2RDU4;B4DF73;B8ZZQ4;F8WE76;Q96EY7;Q96EY7-2
144,gsea,Mitochondrial translation elongation,-0.6785714285714285,-0.9652382520344321,0.5277777777777778,1.0,1.0,1/1,35.09%,PTCD3,B2RDU4;B4DF73;B8ZZQ4;F8WE76;Q96EY7;Q96EY7-2
145,gsea,Mitochondrial translation termination,-0.6785714285714285,-0.9652382520344321,0.5277777777777778,1.0,1.0,1/1,35.09%,PTCD3,B2RDU4;B4DF73;B8ZZQ4;F8WE76;Q96EY7;Q96EY7-2
146,gsea,"Signaling by Rho GTPases, Miro GTPases and RHOBTB3",0.5568727922899848,0.9578099652029721,0.5533536585365854,0.7487875605675045,1.0,1/2,36.84%,ABR,A0A0G2JQ41;B7Z2X0;B7Z683;B7Z7Z1;I3L1U8;I3L379;Q12979;Q12979-2;Q12979-3;Q12979-4;Q6ZT60
147,gsea,RHO GTPase cycle,0.5568727922899848,0.9578099652029721,0.5533536585365854,0.7487875605675045,1.0,1/2,36.84%,ABR,A0A0G2JQ41;B7Z2X0;B7Z683;B7Z7Z1;I3L1U8;I3L379;Q12979;Q12979-2;Q12979-3;Q12979-4;Q6ZT60
148,gsea,Signaling by Rho GTPases,0.5568727922899848,0.9578099652029721,0.5533536585365854,0.7487875605675045,1.0,1/2,36.84%,ABR,A0A0G2JQ41;B7Z2X0;B7Z683;B7Z7Z1;I3L1U8;I3L379;Q12979;Q12979-2;Q12979-3;Q12979-4;Q6ZT60
149,gsea,tRNA processing,-0.6428571428571428,-0.91768826619965,0.5916030534351145,1.0,1.0,1/1,38.60%,EPRS1,B4DKX5;B4DP50;H6WCP5;P07814;Q3KQZ8;V9GYZ6;V9GZ76
150,gsea,tRNA modification in the nucleus and cytosol,-0.6428571428571428,-0.91768826619965,0.5916030534351145,1.0,1.0,1/1,38.60%,EPRS1,B4DKX5;B4DP50;H6WCP5;P07814;Q3KQZ8;V9GYZ6;V9GZ76
151,gsea,Selenoamino acid metabolism,-0.6428571428571428,-0.91768826619965,0.5916030534351145,1.0,1.0,1/1,38.60%,EPRS1,B4DKX5;B4DP50;H6WCP5;P07814;Q3KQZ8;V9GYZ6;V9GZ76
152,gsea,tRNA Aminoacylation,-0.6428571428571428,-0.91768826619965,0.5916030534351145,1.0,1.0,1/1,38.60%,EPRS1,B4DKX5;B4DP50;H6WCP5;P07814;Q3KQZ8;V9GYZ6;V9GZ76
153,gsea,Cytosolic tRNA aminoacylation,-0.6428571428571428,-0.91768826619965,0.5916030534351145,1.0,1.0,1/1,38.60%,EPRS1,B4DKX5;B4DP50;H6WCP5;P07814;Q3KQZ8;V9GYZ6;V9GZ76
154,gsea,Glycogen metabolism,-0.625,-0.9112907128684118,0.6802973977695167,1.0,1.0,1/1,40.35%,PYGM,A0A0M4FEM1;B2RB32;B4DRQ4;B4DRW6;P11217;P11217-2
155,gsea,Glycogen breakdown (glycogenolysis),-0.625,-0.9112907128684118,0.6802973977695167,1.0,1.0,1/1,40.35%,PYGM,A0A0M4FEM1;B2RB32;B4DRQ4;B4DRW6;P11217;P11217-2
156,gsea,Diseases of hemostasis,0.6249999999999999,0.9045795757972696,0.7134502923976608,0.8237638348838544,1.0,1/1,38.60%,SERPING1,A0A0S2Z333;E9KL26;E9PGN7;H0YCA1;H9KV48;P05155;P05155-2;P05155-3;Q5UGI6
157,gsea,Defective SERPING1 causes hereditary angioedema,0.6249999999999999,0.9045795757972696,0.7134502923976608,0.8237638348838544,1.0,1/1,38.60%,SERPING1,A0A0S2Z333;E9KL26;E9PGN7;H0YCA1;H9KV48;P05155;P05155-2;P05155-3;Q5UGI6
158,gsea,Defects of contact activation system (CAS) and kallikrein/kinin system (KKS),0.6249999999999999,0.9045795757972696,0.7134502923976608,0.8237638348838544,1.0,1/1,38.60%,SERPING1,A0A0S2Z333;E9KL26;E9PGN7;H0YCA1;H9KV48;P05155;P05155-2;P05155-3;Q5UGI6
159,gsea,Ion channel transport,-0.48148148148148145,-0.8865434971889753,0.789795918367347,1.0,1.0,3/3,56.14%,ATP6V1H;ATP1A1;ATP2A2,A0A024R7U9;A0A024R7X3;A0A0D9SG68;B3KUZ7;B4E054;E5RG49;E5RHH0;E5RJG1;E5RK31;G3V126;Q8TF11;Q9UI12;Q9UI12-2;B7Z1N5;B7Z3V1;P05023;P05023-2;P05023-3;P05023-4;Q58I23;Q5TC01;Q5TC02;P16615-2
160,gsea,Muscle contraction,-0.5,-0.8703590973712816,0.7864077669902912,1.0,1.0,5/5,56.14%,TMOD1;TMOD3;TMOD4;ATP1A1;ATP2A2,H0YKU1;H0YNJ8;P28289;P28289-2;Q5HYL6;Q9NYL9;Q9NZQ9;Q9NZQ9-2;H0YKU1;H0YNJ8;P28289;P28289-2;Q5HYL6;Q9NYL9;Q9NZQ9;Q9NZQ9-2;H0YKU1;H0YNJ8;P28289;P28289-2;Q5HYL6;Q9NYL9;Q9NZQ9;Q9NZQ9-2;B7Z1N5;B7Z3V1;P05023;P05023-2;P05023-3;P05023-4;Q58I23;Q5TC01;Q5TC02;P16615-2
161,gsea,p75 NTR receptor-mediated signalling,0.6428571428571429,0.8636709824828632,0.6408730158730159,0.8055156194993055,1.0,1/1,36.84%,ABR,A0A0G2JQ41;B7Z2X0;B7Z683;B7Z7Z1;I3L1U8;I3L379;Q12979;Q12979-2;Q12979-3;Q12979-4;Q6ZT60
162,gsea,"Cell death signalling via NRAGE, NRIF and NADE",0.6428571428571429,0.8636709824828632,0.6408730158730159,0.8055156194993055,1.0,1/1,36.84%,ABR,A0A0G2JQ41;B7Z2X0;B7Z683;B7Z7Z1;I3L1U8;I3L379;Q12979;Q12979-2;Q12979-3;Q12979-4;Q6ZT60
163,gsea,Death Receptor Signaling,0.6428571428571429,0.8636709824828632,0.6408730158730159,0.8055156194993055,1.0,1/1,36.84%,ABR,A0A0G2JQ41;B7Z2X0;B7Z683;B7Z7Z1;I3L1U8;I3L379;Q12979;Q12979-2;Q12979-3;Q12979-4;Q6ZT60
164,gsea,RHOC GTPase cycle,0.6428571428571429,0.8636709824828632,0.6408730158730159,0.8055156194993055,1.0,1/1,36.84%,ABR,A0A0G2JQ41;B7Z2X0;B7Z683;B7Z7Z1;I3L1U8;I3L379;Q12979;Q12979-2;Q12979-3;Q12979-4;Q6ZT60
165,gsea,RAC3 GTPase cycle,0.6428571428571429,0.8636709824828632,0.6408730158730159,0.8055156194993055,1.0,1/1,36.84%,ABR,A0A0G2JQ41;B7Z2X0;B7Z683;B7Z7Z1;I3L1U8;I3L379;Q12979;Q12979-2;Q12979-3;Q12979-4;Q6ZT60
166,gsea,NRAGE signals death through JNK,0.6428571428571429,0.8636709824828632,0.6408730158730159,0.8055156194993055,1.0,1/1,36.84%,ABR,A0A0G2JQ41;B7Z2X0;B7Z683;B7Z7Z1;I3L1U8;I3L379;Q12979;Q12979-2;Q12979-3;Q12979-4;Q6ZT60
167,gsea,RHOB GTPase cycle,0.6428571428571429,0.8636709824828632,0.6408730158730159,0.8055156194993055,1.0,1/1,36.84%,ABR,A0A0G2JQ41;B7Z2X0;B7Z683;B7Z7Z1;I3L1U8;I3L379;Q12979;Q12979-2;Q12979-3;Q12979-4;Q6ZT60
168,gsea,RAC2 GTPase cycle,0.6428571428571429,0.8636709824828632,0.6408730158730159,0.8055156194993055,1.0,1/1,36.84%,ABR,A0A0G2JQ41;B7Z2X0;B7Z683;B7Z7Z1;I3L1U8;I3L379;Q12979;Q12979-2;Q12979-3;Q12979-4;Q6ZT60
169,gsea,RHOA GTPase cycle,0.6428571428571429,0.8636709824828632,0.6408730158730159,0.8055156194993055,1.0,1/1,36.84%,ABR,A0A0G2JQ41;B7Z2X0;B7Z683;B7Z7Z1;I3L1U8;I3L379;Q12979;Q12979-2;Q12979-3;Q12979-4;Q6ZT60
170,gsea,RAC1 GTPase cycle,0.6428571428571429,0.8636709824828632,0.6408730158730159,0.8055156194993055,1.0,1/1,36.84%,ABR,A0A0G2JQ41;B7Z2X0;B7Z683;B7Z7Z1;I3L1U8;I3L379;Q12979;Q12979-2;Q12979-3;Q12979-4;Q6ZT60
171,gsea,CDC42 GTPase cycle,0.6428571428571429,0.8636709824828632,0.6408730158730159,0.8055156194993055,1.0,1/1,36.84%,ABR,A0A0G2JQ41;B7Z2X0;B7Z683;B7Z7Z1;I3L1U8;I3L379;Q12979;Q12979-2;Q12979-3;Q12979-4;Q6ZT60
172,gsea,G alpha (12/13) signalling events,0.6428571428571429,0.8636709824828632,0.6408730158730159,0.8055156194993055,1.0,1/1,36.84%,ABR,A0A0G2JQ41;B7Z2X0;B7Z683;B7Z7Z1;I3L1U8;I3L379;Q12979;Q12979-2;Q12979-3;Q12979-4;Q6ZT60
173,gsea,Cellular response to chemical stress,-0.6071428571428571,-0.8608828587808133,0.690566037735849,1.0,1.0,1/1,42.11%,NDUFA4,A0A024R9Z0;O00483
174,gsea,Transcriptional Regulation by TP53,-0.6071428571428571,-0.8608828587808133,0.690566037735849,1.0,1.0,1/1,42.11%,NDUFA4,A0A024R9Z0;O00483
175,gsea,"Respiratory electron transport, ATP synthesis by chemiosmotic coupling, and heat production by uncoupling proteins.",-0.6071428571428571,-0.8608828587808133,0.690566037735849,1.0,1.0,1/1,42.11%,NDUFA4,A0A024R9Z0;O00483
176,gsea,The citric acid (TCA) cycle and respiratory electron transport,-0.6071428571428571,-0.8608828587808133,0.690566037735849,1.0,1.0,1/1,42.11%,NDUFA4,A0A024R9Z0;O00483
177,gsea,Cytoprotection by HMOX1,-0.6071428571428571,-0.8608828587808133,0.690566037735849,1.0,1.0,1/1,42.11%,NDUFA4,A0A024R9Z0;O00483
178,gsea,TP53 Regulates Metabolic Genes,-0.6071428571428571,-0.8608828587808133,0.690566037735849,1.0,1.0,1/1,42.11%,NDUFA4,A0A024R9Z0;O00483
179,gsea,Respiratory electron transport,-0.6071428571428571,-0.8608828587808133,0.690566037735849,1.0,1.0,1/1,42.11%,NDUFA4,A0A024R9Z0;O00483
180,gsea,Iron uptake and transport,0.46574411369122076,0.8452500605873087,0.6723338485316847,0.8281540232260506,1.0,1/2,42.11%,CP,A5PL27;A8K5A4;B3KTA8;B7Z5Q2;D6RE86;H7C5N5;P00450;Q1L857;Q6NSB2
181,gsea,Fatty acid metabolism,-0.5283018867924528,-0.8410422075100561,0.7409523809523809,1.0,1.0,4/4,52.63%,CPT1A;ACSL1;ACSL5;ACSL6,A0A024R5F4;B2RAQ8;P50416;P50416-2;A8K9T3;B2RB13;B3KV64;B4DFW3;B4DX30;B4E0R0;B7Z3Z9;D6RER0;D6RG07;E7EPM6;E7ERD7;H0Y9U7;H0Y9Z9;P33121;P33121-2;P33121-3;Q108N1;Q108N2;Q9UKU0;Q9UKU0-1;Q9UKU0-2;Q9UKU0-3;Q9UKU0-5;Q9UKU0-6;Q9UKU0-7;Q9UKU0-8;Q9UKU0-9;Q9ULC5;Q9ULC5-3;Q9ULC5-4;A8K9T3;B2RB13;B3KV64;B4DFW3;B4DX30;B4E0R0;B7Z3Z9;D6RER0;D6RG07;E7EPM6;E7ERD7;H0Y9U7;H0Y9Z9;P33121;P33121-2;P33121-3;Q108N1;Q108N2;Q9UKU0;Q9UKU0-1;Q9UKU0-2;Q9UKU0-3;Q9UKU0-5;Q9UKU0-6;Q9UKU0-7;Q9UKU0-8;Q9UKU0-9;Q9ULC5;Q9ULC5-3;Q9ULC5-4;A8K9T3;B2RB13;B3KV64;B4DFW3;B4DX30;B4E0R0;B7Z3Z9;D6RER0;D6RG07;E7EPM6;E7ERD7;H0Y9U7;H0Y9Z9;P33121;P33121-2;P33121-3;Q108N1;Q108N2;Q9UKU0;Q9UKU0-1;Q9UKU0-2;Q9UKU0-3;Q9UKU0-5;Q9UKU0-6;Q9UKU0-7;Q9UKU0-8;Q9UKU0-9;Q9ULC5;Q9ULC5-3;Q9ULC5-4
182,gsea,Carnitine metabolism,-0.5892857142857143,-0.83900958163362,0.7593283582089553,0.9929207802244451,1.0,1/1,43.86%,CPT1A,A0A024R5F4;B2RAQ8;P50416;P50416-2
183,gsea,Signaling by Retinoic Acid,-0.5892857142857143,-0.83900958163362,0.7593283582089553,0.9929207802244451,1.0,1/1,43.86%,CPT1A,A0A024R5F4;B2RAQ8;P50416;P50416-2
184,gsea,RORA activates gene expression,-0.5892857142857143,-0.83900958163362,0.7593283582089553,0.9929207802244451,1.0,1/1,43.86%,CPT1A,A0A024R5F4;B2RAQ8;P50416;P50416-2
185,gsea,Signaling by Nuclear Receptors,-0.5892857142857143,-0.83900958163362,0.7593283582089553,0.9929207802244451,1.0,1/1,43.86%,CPT1A,A0A024R5F4;B2RAQ8;P50416;P50416-2
186,gsea,Metal ion SLC transporters,0.5892857142857143,0.8336070324574952,0.7762906309751434,0.7999844020766508,1.0,1/1,42.11%,CP,A5PL27;A8K5A4;B3KTA8;B7Z5Q2;D6RE86;H7C5N5;P00450;Q1L857;Q6NSB2
187,gsea,SLC transporter disorders,0.5892857142857143,0.8336070324574952,0.7762906309751434,0.7999844020766508,1.0,1/1,42.11%,CP,A5PL27;A8K5A4;B3KTA8;B7Z5Q2;D6RE86;H7C5N5;P00450;Q1L857;Q6NSB2
188,gsea,Defective SLC40A1 causes hemochromatosis 4 (HFE4) (macrophages),0.5892857142857143,0.8336070324574952,0.7762906309751434,0.7999844020766508,1.0,1/1,42.11%,CP,A5PL27;A8K5A4;B3KTA8;B7Z5Q2;D6RE86;H7C5N5;P00450;Q1L857;Q6NSB2
189,gsea,"Transport of bile salts and organic acids, metal ions and amine compounds",0.5892857142857143,0.8336070324574952,0.7762906309751434,0.7999844020766508,1.0,1/1,42.11%,CP,A5PL27;A8K5A4;B3KTA8;B7Z5Q2;D6RE86;H7C5N5;P00450;Q1L857;Q6NSB2
190,gsea,SLC-mediated transmembrane transport,0.5892857142857143,0.8336070324574952,0.7762906309751434,0.7999844020766508,1.0,1/1,42.11%,CP,A5PL27;A8K5A4;B3KTA8;B7Z5Q2;D6RE86;H7C5N5;P00450;Q1L857;Q6NSB2
191,gsea,Defective CP causes aceruloplasminemia (ACERULOP),0.5892857142857143,0.8336070324574952,0.7762906309751434,0.7999844020766508,1.0,1/1,42.11%,CP,A5PL27;A8K5A4;B3KTA8;B7Z5Q2;D6RE86;H7C5N5;P00450;Q1L857;Q6NSB2
192,gsea,"Nucleotide-binding domain, leucine rich repeat containing receptor (NLR) signaling pathways",-0.5535714285714285,-0.8123920771965467,0.8217054263565892,0.9566832236989304,1.0,1/1,47.37%,SUGT1,A8K5T7;A8K7W3;B4DYC6;Q9P1S2;Q9Y2Z0;Q9Y2Z0-2
193,gsea,Inflammasomes,-0.5535714285714285,-0.8123920771965467,0.8217054263565892,0.9566832236989304,1.0,1/1,47.37%,SUGT1,A8K5T7;A8K7W3;B4DYC6;Q9P1S2;Q9Y2Z0;Q9Y2Z0-2
194,gsea,Cell recruitment (pro-inflammatory response),-0.5535714285714285,-0.8123920771965467,0.8217054263565892,0.9566832236989304,1.0,1/1,47.37%,SUGT1,A8K5T7;A8K7W3;B4DYC6;Q9P1S2;Q9Y2Z0;Q9Y2Z0-2
195,gsea,Leishmania infection,-0.5535714285714285,-0.8123920771965467,0.8217054263565892,0.9566832236989304,1.0,1/1,47.37%,SUGT1,A8K5T7;A8K7W3;B4DYC6;Q9P1S2;Q9Y2Z0;Q9Y2Z0-2
196,gsea,Parasitic Infection Pathways,-0.5535714285714285,-0.8123920771965467,0.8217054263565892,0.9566832236989304,1.0,1/1,47.37%,SUGT1,A8K5T7;A8K7W3;B4DYC6;Q9P1S2;Q9Y2Z0;Q9Y2Z0-2
197,gsea,Purinergic signaling in leishmaniasis infection,-0.5535714285714285,-0.8123920771965467,0.8217054263565892,0.9566832236989304,1.0,1/1,47.37%,SUGT1,A8K5T7;A8K7W3;B4DYC6;Q9P1S2;Q9Y2Z0;Q9Y2Z0-2
198,gsea,The NLRP3 inflammasome,-0.5535714285714285,-0.8123920771965467,0.8217054263565892,0.9566832236989304,1.0,1/1,47.37%,SUGT1,A8K5T7;A8K7W3;B4DYC6;Q9P1S2;Q9Y2Z0;Q9Y2Z0-2
199,gsea,Platelet homeostasis,0.5357142857142858,0.812096300645919,0.8763557483731019,0.7924535475774684,1.0,1/1,47.37%,ATP2A2,P16615-2
200,gsea,Pre-NOTCH Expression and Processing,0.5357142857142858,0.812096300645919,0.8763557483731019,0.7924535475774684,1.0,1/1,47.37%,ATP2A2,P16615-2
201,gsea,Pre-NOTCH Processing in Golgi,0.5357142857142858,0.812096300645919,0.8763557483731019,0.7924535475774684,1.0,1/1,47.37%,ATP2A2,P16615-2
202,gsea,Reduction of cytosolic Ca++ levels,0.5357142857142858,0.812096300645919,0.8763557483731019,0.7924535475774684,1.0,1/1,47.37%,ATP2A2,P16615-2
203,gsea,Signaling by NOTCH,0.5357142857142858,0.812096300645919,0.8763557483731019,0.7924535475774684,1.0,1/1,47.37%,ATP2A2,P16615-2
204,gsea,Platelet calcium homeostasis,0.5357142857142858,0.812096300645919,0.8763557483731019,0.7924535475774684,1.0,1/1,47.37%,ATP2A2,P16615-2
205,gsea,Neddylation,-0.5714285714285714,-0.8118555464965712,0.8071833648393195,0.8545903351581965,1.0,1/1,45.61%,COPS5,A0A024R7W9;E5RFS1;E5RG35;E5RHF2;E5RHH5;E5RK55;H0UI27;Q59GH5;Q92905
206,gsea,Transcription-Coupled Nucleotide Excision Repair (TC-NER),-0.5714285714285714,-0.8118555464965712,0.8071833648393195,0.8545903351581965,1.0,1/1,45.61%,COPS5,A0A024R7W9;E5RFS1;E5RG35;E5RHF2;E5RHH5;E5RK55;H0UI27;Q59GH5;Q92905
207,gsea,Membrane Trafficking,-0.5714285714285714,-0.8118555464965712,0.8071833648393195,0.8545903351581965,1.0,1/1,45.61%,COPS5,A0A024R7W9;E5RFS1;E5RG35;E5RHF2;E5RHH5;E5RK55;H0UI27;Q59GH5;Q92905
208,gsea,Formation of TC-NER Pre-Incision Complex,-0.5714285714285714,-0.8118555464965712,0.8071833648393195,0.8545903351581965,1.0,1/1,45.61%,COPS5,A0A024R7W9;E5RFS1;E5RG35;E5RHF2;E5RHH5;E5RK55;H0UI27;Q59GH5;Q92905
209,gsea,DNA Damage Recognition in GG-NER,-0.5714285714285714,-0.8118555464965712,0.8071833648393195,0.8545903351581965,1.0,1/1,45.61%,COPS5,A0A024R7W9;E5RFS1;E5RG35;E5RHF2;E5RHH5;E5RK55;H0UI27;Q59GH5;Q92905
210,gsea,Nucleotide Excision Repair,-0.5714285714285714,-0.8118555464965712,0.8071833648393195,0.8545903351581965,1.0,1/1,45.61%,COPS5,A0A024R7W9;E5RFS1;E5RG35;E5RHF2;E5RHH5;E5RK55;H0UI27;Q59GH5;Q92905
211,gsea,Cargo recognition for clathrin-mediated endocytosis,-0.5714285714285714,-0.8118555464965712,0.8071833648393195,0.8545903351581965,1.0,1/1,45.61%,COPS5,A0A024R7W9;E5RFS1;E5RG35;E5RHF2;E5RHH5;E5RK55;H0UI27;Q59GH5;Q92905
212,gsea,Clathrin-mediated endocytosis,-0.5714285714285714,-0.8118555464965712,0.8071833648393195,0.8545903351581965,1.0,1/1,45.61%,COPS5,A0A024R7W9;E5RFS1;E5RG35;E5RHF2;E5RHH5;E5RK55;H0UI27;Q59GH5;Q92905
213,gsea,Global Genome Nucleotide Excision Repair (GG-NER),-0.5714285714285714,-0.8118555464965712,0.8071833648393195,0.8545903351581965,1.0,1/1,45.61%,COPS5,A0A024R7W9;E5RFS1;E5RG35;E5RHF2;E5RHH5;E5RK55;H0UI27;Q59GH5;Q92905
214,gsea,DNA Repair,-0.5714285714285714,-0.8118555464965712,0.8071833648393195,0.8545903351581965,1.0,1/1,45.61%,COPS5,A0A024R7W9;E5RFS1;E5RG35;E5RHF2;E5RHH5;E5RK55;H0UI27;Q59GH5;Q92905
215,gsea,Cardiac conduction,-0.4727272727272727,-0.8020857166595493,0.8929292929292929,0.8430294084883591,1.0,2/2,56.14%,ATP1A1;ATP2A2,B7Z1N5;B7Z3V1;P05023;P05023-2;P05023-3;P05023-4;Q58I23;Q5TC01;Q5TC02;P16615-2
216,gsea,Ion transport by P-type ATPases,-0.4727272727272727,-0.8020857166595493,0.8929292929292929,0.8430294084883591,1.0,2/2,56.14%,ATP1A1;ATP2A2,B7Z1N5;B7Z3V1;P05023;P05023-2;P05023-3;P05023-4;Q58I23;Q5TC01;Q5TC02;P16615-2
217,gsea,Ion homeostasis,-0.4727272727272727,-0.8020857166595493,0.8929292929292929,0.8430294084883591,1.0,2/2,56.14%,ATP1A1;ATP2A2,B7Z1N5;B7Z3V1;P05023;P05023-2;P05023-3;P05023-4;Q58I23;Q5TC01;Q5TC02;P16615-2
218,gsea,Metabolism of lipids,0.3798629770504864,0.793682272610874,0.7791519434628975,0.8148725903719455,1.0,5/6,59.65%,APOA1;ACSL6;ACSL5;ACSL1;CPT1A,A0A024R3E3;F8W696;P02647;Q8TDB0;Q9Y355;A8K9T3;B2RB13;B3KV64;B4DFW3;B4DX30;B4E0R0;B7Z3Z9;D6RER0;D6RG07;E7EPM6;E7ERD7;H0Y9U7;H0Y9Z9;P33121;P33121-2;P33121-3;Q108N1;Q108N2;Q9UKU0;Q9UKU0-1;Q9UKU0-2;Q9UKU0-3;Q9UKU0-5;Q9UKU0-6;Q9UKU0-7;Q9UKU0-8;Q9UKU0-9;Q9ULC5;Q9ULC5-3;Q9ULC5-4;A8K9T3;B2RB13;B3KV64;B4DFW3;B4DX30;B4E0R0;B7Z3Z9;D6RER0;D6RG07;E7EPM6;E7ERD7;H0Y9U7;H0Y9Z9;P33121;P33121-2;P33121-3;Q108N1;Q108N2;Q9UKU0;Q9UKU0-1;Q9UKU0-2;Q9UKU0-3;Q9UKU0-5;Q9UKU0-6;Q9UKU0-7;Q9UKU0-8;Q9UKU0-9;Q9ULC5;Q9ULC5-3;Q9ULC5-4;A8K9T3;B2RB13;B3KV64;B4DFW3;B4DX30;B4E0R0;B7Z3Z9;D6RER0;D6RG07;E7EPM6;E7ERD7;H0Y9U7;H0Y9Z9;P33121;P33121-2;P33121-3;Q108N1;Q108N2;Q9UKU0;Q9UKU0-1;Q9UKU0-2;Q9UKU0-3;Q9UKU0-5;Q9UKU0-6;Q9UKU0-7;Q9UKU0-8;Q9UKU0-9;Q9ULC5;Q9ULC5-3;Q9ULC5-4;A0A024R5F4;B2RAQ8;P50416;P50416-2
219,gsea,alpha-linolenic (omega3) and linoleic (omega6) acid metabolism,-0.5357142857142857,-0.7718742934659724,0.8664323374340949,0.8604053958671544,1.0,1/1,49.12%,ACSL1,A8K9T3;B2RB13;B3KV64;B4DFW3;B4DX30;B4E0R0;B7Z3Z9;D6RER0;D6RG07;E7EPM6;E7ERD7;H0Y9U7;H0Y9Z9;P33121;P33121-2;P33121-3;Q108N1;Q108N2;Q9UKU0;Q9UKU0-1;Q9UKU0-2;Q9UKU0-3;Q9UKU0-5;Q9UKU0-6;Q9UKU0-7;Q9UKU0-8;Q9UKU0-9;Q9ULC5;Q9ULC5-3;Q9ULC5-4
220,gsea,Linoleic acid (LA) metabolism,-0.5357142857142857,-0.7718742934659724,0.8664323374340949,0.8604053958671544,1.0,1/1,49.12%,ACSL1,A8K9T3;B2RB13;B3KV64;B4DFW3;B4DX30;B4E0R0;B7Z3Z9;D6RER0;D6RG07;E7EPM6;E7ERD7;H0Y9U7;H0Y9Z9;P33121;P33121-2;P33121-3;Q108N1;Q108N2;Q9UKU0;Q9UKU0-1;Q9UKU0-2;Q9UKU0-3;Q9UKU0-5;Q9UKU0-6;Q9UKU0-7;Q9UKU0-8;Q9UKU0-9;Q9ULC5;Q9ULC5-3;Q9ULC5-4
221,gsea,alpha-linolenic acid (ALA) metabolism,-0.5357142857142857,-0.7718742934659724,0.8664323374340949,0.8604053958671544,1.0,1/1,49.12%,ACSL1,A8K9T3;B2RB13;B3KV64;B4DFW3;B4DX30;B4E0R0;B7Z3Z9;D6RER0;D6RG07;E7EPM6;E7ERD7;H0Y9U7;H0Y9Z9;P33121;P33121-2;P33121-3;Q108N1;Q108N2;Q9UKU0;Q9UKU0-1;Q9UKU0-2;Q9UKU0-3;Q9UKU0-5;Q9UKU0-6;Q9UKU0-7;Q9UKU0-8;Q9UKU0-9;Q9ULC5;Q9ULC5-3;Q9ULC5-4
222,gsea,Synthesis of very long-chain fatty acyl-CoAs,-0.5185185185185185,-0.7409056412851007,0.9426386233269598,0.8885878519386373,1.0,3/3,52.63%,ACSL1;ACSL5;ACSL6,A8K9T3;B2RB13;B3KV64;B4DFW3;B4DX30;B4E0R0;B7Z3Z9;D6RER0;D6RG07;E7EPM6;E7ERD7;H0Y9U7;H0Y9Z9;P33121;P33121-2;P33121-3;Q108N1;Q108N2;Q9UKU0;Q9UKU0-1;Q9UKU0-2;Q9UKU0-3;Q9UKU0-5;Q9UKU0-6;Q9UKU0-7;Q9UKU0-8;Q9UKU0-9;Q9ULC5;Q9ULC5-3;Q9ULC5-4;A8K9T3;B2RB13;B3KV64;B4DFW3;B4DX30;B4E0R0;B7Z3Z9;D6RER0;D6RG07;E7EPM6;E7ERD7;H0Y9U7;H0Y9Z9;P33121;P33121-2;P33121-3;Q108N1;Q108N2;Q9UKU0;Q9UKU0-1;Q9UKU0-2;Q9UKU0-3;Q9UKU0-5;Q9UKU0-6;Q9UKU0-7;Q9UKU0-8;Q9UKU0-9;Q9ULC5;Q9ULC5-3;Q9ULC5-4;A8K9T3;B2RB13;B3KV64;B4DFW3;B4DX30;B4E0R0;B7Z3Z9;D6RER0;D6RG07;E7EPM6;E7ERD7;H0Y9U7;H0Y9Z9;P33121;P33121-2;P33121-3;Q108N1;Q108N2;Q9UKU0;Q9UKU0-1;Q9UKU0-2;Q9UKU0-3;Q9UKU0-5;Q9UKU0-6;Q9UKU0-7;Q9UKU0-8;Q9UKU0-9;Q9ULC5;Q9ULC5-3;Q9ULC5-4
223,gsea,Fatty acyl-CoA biosynthesis,-0.5185185185185185,-0.7409056412851007,0.9426386233269598,0.8885878519386373,1.0,3/3,52.63%,ACSL1;ACSL5;ACSL6,A8K9T3;B2RB13;B3KV64;B4DFW3;B4DX30;B4E0R0;B7Z3Z9;D6RER0;D6RG07;E7EPM6;E7ERD7;H0Y9U7;H0Y9Z9;P33121;P33121-2;P33121-3;Q108N1;Q108N2;Q9UKU0;Q9UKU0-1;Q9UKU0-2;Q9UKU0-3;Q9UKU0-5;Q9UKU0-6;Q9UKU0-7;Q9UKU0-8;Q9UKU0-9;Q9ULC5;Q9ULC5-3;Q9ULC5-4;A8K9T3;B2RB13;B3KV64;B4DFW3;B4DX30;B4E0R0;B7Z3Z9;D6RER0;D6RG07;E7EPM6;E7ERD7;H0Y9U7;H0Y9Z9;P33121;P33121-2;P33121-3;Q108N1;Q108N2;Q9UKU0;Q9UKU0-1;Q9UKU0-2;Q9UKU0-3;Q9UKU0-5;Q9UKU0-6;Q9UKU0-7;Q9UKU0-8;Q9UKU0-9;Q9ULC5;Q9ULC5-3;Q9ULC5-4;A8K9T3;B2RB13;B3KV64;B4DFW3;B4DX30;B4E0R0;B7Z3Z9;D6RER0;D6RG07;E7EPM6;E7ERD7;H0Y9U7;H0Y9Z9;P33121;P33121-2;P33121-3;Q108N1;Q108N2;Q9UKU0;Q9UKU0-1;Q9UKU0-2;Q9UKU0-3;Q9UKU0-5;Q9UKU0-6;Q9UKU0-7;Q9UKU0-8;Q9UKU0-9;Q9ULC5;Q9ULC5-3;Q9ULC5-4
